Risk Factors and Prediction Model for Persistent Breast-cancer-related Lymphedema: a 5-year Cohort Study
Overview
Oncology
Authors
Affiliations
Purpose: Breast-cancer-related lymphedema (BCRL) can be a transient or persistent condition. The aims of this study were to (1) identify and weigh the risk factors for persistent lymphedema (PLE) among all patients with BCRL and (2) establish a prediction model for the occurrence of PLE.
Methods: A cohort of 342 patients with BCRL with a median follow-up of 5 years after the onset of swelling was analyzed. PLE was defined as a hardening of the subcutaneous tissue, the persistence of the circumferential difference (CD) between arms, or a flare-up of swelling during follow-up. Multiple logistic regression was used to identify risk factors for PLE, including tumors, treatments, and patient-related factors. The prediction accuracy of the model was assessed using the area under the receiver operating characteristic curve (AUC).
Results: Of the 342 patients with BCRL, 229 (67%) had PLE. Multiple logistic regression analysis revealed that the number of lymph node metastases (p = 0.012), the maximal CD between arms at the first occurrence of swelling (p < 0.001), and the largest difference during follow-up (p < 0.001) were significant predictors for PLE. The corresponding AUC was 0.908. Although inclusion of body weight gains (p = 0.008) and maximal CD at the latest follow-up (p = 0.002) increased the analytical accuracy (AUC = 0.920), the resulting AUC values (p = 0.113) were not significantly different.
Conclusions: BCRL is persistent in two thirds of patients. Patients with more lymph node metastases, weight gain, and larger CD since the onset of swelling and during follow-up have an increased likelihood of developing PLE.
Coleman-Belin J, Rubin J, Boe L, Diwan R, Monge J, Dinh D Ann Surg Oncol. 2025; .
PMID: 39899216 DOI: 10.1245/s10434-025-16918-5.
External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.
Lin C, Su J, Wu A, Lin N, Hossack M, Shi W JAMA Netw Open. 2025; 8(1):e2455383.
PMID: 39836421 PMC: 11751742. DOI: 10.1001/jamanetworkopen.2024.55383.
Fu J, Chen R, He L, Bao L, Lin Z, Jiang W Front Oncol. 2024; 14:1436748.
PMID: 39600650 PMC: 11590064. DOI: 10.3389/fonc.2024.1436748.
Development and validation of a nomogram for breast cancer-related lymphedema.
Jiang Q, Hu H, Liao J, Li Z, Tan J Sci Rep. 2024; 14(1):15602.
PMID: 38971880 PMC: 11227568. DOI: 10.1038/s41598-024-66573-1.
Development of predictive models for lymphedema by using blood tests and therapy data.
Trinh X, Chien P, Long N, Van Anh L, Giang N, Nam S Sci Rep. 2023; 13(1):19720.
PMID: 37957217 PMC: 10643602. DOI: 10.1038/s41598-023-46567-1.